secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jounce Therapeutics, Inc. (—)
CIK:        0001640455
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001640455-23-000040
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 1.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jounce to be acquired by Concentra for $1.85 cash + CVR per share; terminates Redx deal
--------------------------------------------------------------------------------

- Concentra will acquire all Jounce shares via tender offer at $1.85 cash/share plus one CVR; ~75% premium to unaffected price.
- CVR entitles holders to 80% of net proceeds from any license/disposition of JTX-8064, pimivalimab, vopratelimab, and two pre-clinical programs within 2 years of close.
- Jounce terminates prior co-operation agreement with Redx (all-share merger) and RM3 merger agreement; no termination fees.
- Jounce reduces workforce by ~84%; expects $6.5M in pre-tax charges in Q2 2023.
- Tang Capital Partners, LP commits $100M equity to fund the transaction; offer expected to close in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/0001640455-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000040/jnce-20230326.htm
  HTML page:      https://secwatch.observer/filing/0001640455-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer